Lv7
4430 积分 2020-07-11 加入
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)
8小时前
已完结
Report on Cardiovascular Health and Diseases in China 2025: An Updated Summary
6天前
已关闭
Tirzepatide vs. Semaglutide for Obesity Treatment
1个月前
已完结
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
1个月前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial
2个月前
已关闭
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study
2个月前
已完结
Development and validation of a noninvasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery
3个月前
已完结
American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum
3个月前
已完结
Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use
3个月前
已完结
GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events
4个月前
已完结
皖公网安备34019202002308
